3 Timeless Lessons Every Investor Can Learn From Valeant Pharmaceuticals’ Crash
Valeant Pharmaceuticals plunged more than 45% after the once high-flying Canadian biotech company reported earnings, slashed guidance and warned of a potential default. There are many important lessons investors can learn (or relearn) from the collapse in $VRX and I will cover three of them today.